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Abstract
The amount and the types of glycosaminoglycans (GAGs) present in human pancreatic carcinoma were examined and
compared with those in normal pancreas. Human pancreatic carcinoma contained increased levels (4-fold) of total GAGs.
Particularly, this carcinoma is characterized by a 12-fold increase of hyaluronan (HA) and a 22-fold increase in chondroitin
sulfate (CS) content. CS in pancreatic carcinoma exhibited an altered disaccharide composition which is associated with
marked increase of non-sulfated and 6-sulfated disaccharides. Dermatan sulfate (DS) was also increased (1.5-fold) in
carcinoma, whereas heparan sulfate (HS), the major GAG of normal pancreas, becomes the minor GAG in pancreatic
carcinoma without significant changes in the content and in molecular size. In all cases, the galactosaminoglycans
(GalGAGs, i.e. CS and DS) derived from pancreatic carcinomas were of lower molecular size compared to those from
normal pancreas. The results in this study indicate, for the first time, that human pancreatic carcinoma is characterized by
highly increased amounts of HA and of a structurally altered CS. ß 2000 Elsevier Science B.V. All rights reserved.
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Glycosaminoglycans (GAGs) are highly anionic
macromolecules, which are the major components
of cell surface and extracellular matrix [1]. The
GAG molecules, because of their complex poly-
anionic nature, have been implicated in a number
of biological processes and functions [2,3]. In recent
years, GAGs contained in a wide variety of tumors
have been studied and, in some instances, their chem-
ical and structural characteristics were compared
with the GAGs from normal tissues [4^12]. Pancre-
atic carcinoma, which is one of the common malig-
nant tumors in human, is of unfavorable prognosis
with the highest frequency of mortality and poor
survival time. One of the most pathological charac-
teristics of this carcinoma is its early invasion of the
surrounding tissues and the metastasis to lymph nodes,
liver, lung, peritoneum and bones [13]. Although
GAGs have been characterized from a wide variety
of normal and neoplastic tissues, very little is known
about GAG content, composition and structural
modi¢cations in human pancreas and pancreatic car-
cinoma. In fact, information on these molecules in
pancreatic tissues based mainly on immunohisto-
chemical studies [14^17]. In the present study, the
type of GAGs, their composition and ¢ne chemical
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structure were examined in poorly di¡erentiated pan-
creatic carcinoma and normal pancreas. The results
indicated signi¢cant quantitative changes of GAGs
in pancreatic carcinoma. Furthermore, signi¢cant
structural modi¢cations regarding the sulfation pat-
tern and the molecular size of particular GAGs were
also noted.
Sepharose CL-6B and DEAE-Sephacel were ob-
tained from Pharmacia (Uppsala, Sweden). Papain
twice crystallized, chondroitinases ABC and B (Fla-
vobacterium heparinum) and GAGs standards were
from Sigma (St. Louis, MO, USA). All other chem-
icals used were of the best commercially available
grade. Uronic acid was determined by the Bitter^
Muir modi¢ed carbazole reaction [18]. Analysis for
glucosamine and galactosamine was performed on a
Beckman amino acid analyzer [19]. Unsaturated di-
saccharides released following treatment of GAGs
with chondroitinase ABC were determined by high-
performance liquid chromatography (HPLC) [20].
Determination of glucuronic acid and iduronic acid
was also performed by HPLC [21]. Pancreatic carci-
nomas were collected over a period of 30 months
from 12 patients (7 males/5 females) aged 45^65
years who underwent pancreatectomy for pancreatic
adenocarcinoma in the University Hospital of Patras.
A specimen was taken from the center of the tumor
(approximately 1 g) for pathological and biochemical
examinations. Pathological examination of the neo-
plastic tissue showed poorly di¡erentiated adenocar-
cinoma in 9 of the 12 cases. Normal human pancreas
specimens were collected from ¢ve autopsies (3 males
and 2 females) aged 45^65 years and were free from
speci¢c histopathological changes. All specimens
were immediately stored at 370‡C. Normal pancreas
(n = 5) and poorly di¡erentiated pancreatic carcino-
mas (n = 9) have been separately analyzed for their
GAG content.
Particularly, known amounts of wet weight of tis-
sues (normal and cancerous) were exhaustively di-
gested with papain and the liberated GAG chains
were precipitated by the addition of 5 vols. of etha-
nol. Consequently, GAG chains were further re-
leased from remaining peptide fragments by treat-
ment with 0.05 M NaOH/1 M sodium borohydride
at 45‡C for 48 h under vacuum [22]. The solutions
were brought to pH 5.0, with glacial acetic acid and
the GAGs precipitated with 5 vols. of ethanol. The
GAG content was estimated in each sample by mea-
suring the uronic acid in the precipitates. No signi¢-
cant intrabatch di¡erences were found in GAG con-
tents between the various normal pancreas examined
and between the various pancreatic carcinoma. Fur-
ther analyses were performed on pooled normal pan-
creas and pancreatic carcinoma. Pooled GAGs were
fractionated on a DEAE-Sephacel column as de-
scribed elsewhere [23]. Characterization and quanti-
tation of GAGs were performed following cellulose
acetate electrophoresis [12], hexosamine analysis and
treatment with speci¢c chondro-/dermato-lyases. Di-
saccharide composition and sulfation pattern of ga-
lactosaminoglycans (GalGAGs) were estimated fol-
lowing digestion with chondroitinase ABC and
HPLC analysis. Gel chromatographies and enzymic
degradations were performed as described previously
[12,24]. Digestion with chondroitinase B was per-
formed in 0.05 M Tris^HCl, pH 8.0, containing
0.05% (w/v) bovine serum albumin, at 37‡C for 24
h using 0.3 U enzyme per mg uronic acid. Statistical
analysis was performed by the t-test using the micro-
call origin software (version 3.2). Data reported are
the means þ S.D.
The results on the chemical composition (Table
1A) indicated that no signi¢cant intrabatch di¡eren-
ces were found in the GAG contents, between the
normal pancreas (320 þ 12 Wg of uronic acid/g wet
weight of tissue) and the pancreatic carcinomas
(1615 þ 54 Wg of uronic acid/g wet weight of tissue)
examined. For these reasons, further analyses were
performed on pooled normal pancreas and pancreat-
ic carcinomas. The overall GAG content in pancre-
atic carcinoma was found signi¢cantly increased (4-
fold, P9 0.001) as compared to normal pancreas.
Pancreatic carcinoma is characterized by an 8.5-
fold net increase in GalGAGs content and a 1.6-
fold net increase in glucosaminoglycans (GlcGAGs)
content as indicated by the amounts of galactos-
amine (GalN) and glucosamine (GlcN) (Table 1A).
The molar ratios of GlcA/IdoA and GalN/IdoA re-
vealed that total GAGs and GalGAGs in pancreatic
carcinoma contained relatively lower proportions of
iduronic acid in comparison to those of normal pan-
creas (Table 1A).
Anion-exchange chromatography on DEAE-Seph-
acel revealed the presence of three uronic acid con-
taining populations in both normal and cancerous
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tissues (Fig. 1A). The major population II of normal
tissue (55% of the uronic acid-containing material)
was eluted with 0.5 M NaCl. The remaining pro-
portion of the recovered uronic acid-containing
material was present in population I (9%) and pop-
ulation III (36%). In pancreatic carcinoma, however,
population III was the major population, containing
the 67% of total recovered uronic acid and eluted
with 0.7 M NaCl. The remaining proportion of ur-
onic acid was distributed in populations I (24%) and
II (9%). Populations I, II and III were pooled, as
indicated by bars, concentrated and taken for further
analyses. Electrophoresis of all populations on cellu-
lose acetate membranes (Fig. 1B) revealed that pop-
ulation I migrated with a mobility identical to that of
standard hyaluronan (HA) and population II mi-
grated as standard HS in both tissues. Population
III gave two bands with the same electrophoretic
mobility as that of standards of dermatan sulfate
(DS) and chondroitin sulfate (CS). Chemical analyses
of the populations I and II from both tissues showed
that these populations contained only glucosamine
con¢rming their HA and HS nature, respectively.
The population III contained predominantly
(s 98%) galactosamine and, therefore, appeared to
be GalGAGs. Populations I, II and III, namely, HA,
HS and GalGAGs, respectively, quanti¢ed in terms
of uronic acid and by cellulose acetate electrophore-
sis [12]. It must be noted, that the quantitation of
GAGs by uronic acid analysis was in very close
agreement with that obtained by electrophoretic de-
termination. The results on the composition of
GAGs in normal and cancerous tissues are presented
in Table 1B. Normal pancreas contained mainly HS,
corresponding to 55% of total GAGs. The minor
type of GAG in normal pancreas was the HA
(9%). The GalGAGs were composed of DS (24%)
and CS (12%). In pancreatic carcinoma the CS was
(55%), showing a dramatic increase (22-fold) as com-
pared to normal pancreas. HA content was also sig-
ni¢cantly increased 12-times, whereas DS content
was increased only 1.5-times. In contrast, the amount
of HS was almost unchanged.
These results demonstrated that pancreatic carci-
noma exhibits a statistically signi¢cant increase in
GalGAGs content, which is mainly due to the in-
crease of CS content. The increase in GlcGAGs con-
tent in pancreatic carcinoma is due to the increase of
HA. Previous studies have shown that the amounts
and composition of GAGs undergo dramatic
changes in various neoplastic tissues [8,9,12]. CS con-
tent markedly a¡ected in a variety of neoplasms of
both epithelial and mesenchymal origin [6,7,25] and
increased 12-, 9- and 24-fold in human colon carci-
noma [8], rectum carcinoma [12] and hepatocellular
carcinoma [9], respectively. In the present study, the
22-fold increase of CS in pancreatic carcinoma is of
the same magnitude to that of hepatocellular carci-
noma. The characteristic increase of HA in pancre-
atic carcinoma may possibly be related to the degree
of malignancy of this carcinoma since most malig-
nant solid tumors contain and/or produce increased
Table 1
(A) Chemical composition and (B) GAG distribution, of isolated GAGs from normal pancreas (n = 5) and pancreatic carcinomas
(n = 9)a
Normal pancreas pancreatic carcinoma Net increase (x-fold)
(A) Chemical composition
Uronic acid 320 þ 12 1615 þ 54 4.0
Galactosamine 125 þ 5 1190 þ 43 8.5




Hyaluronan 29 þ 3 (9) 388 þ 32 (24) 12.0
Heparan sulfate 176 þ 16 (55) 145 þ 12 (9) ^
Dermatan sulfate 77 þ 6 (24) 194 þ 16 (12) 1.5
Chondroitin sulfate 38 þ 3 (12) 888 þ 72 (55) 22.0
aThe results are expressed as Wg/g wet weight of tissue. Values are the mean þ S.D. Percent values are given in parentheses.
bMolar ratios of glucuronic acid (GlcA) to iduronic acid (IdoA) and N-acetyl-galactosamine (GalN) to iduronic acid (IdoA).
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amounts of HA. The increase of HA may correlate
with poor di¡erentiation and decreased survival rates
in some human carcinomas [2]. The accumulation of
GAGs, in particular, of HA and CS, in the extracel-
lular matrix surrounding the tumor could play an
important role for the remodeling and reconstruction
of an environment which supports cellular prolifera-
tion and invasion via a hydrated GAG-rich pericel-
lular matrix. On the other hand, the relative small
proportion of DS (as percentage of total net increase
of GalGAGs) could result in an altered extracellular
matrix since L-iduronic acid residues of DS [26] are
directly involved in the orderly arrangement of col-
lagen ¢brils [27]. The resulting less organized extra-
cellular matrix may favor the in¢ltration of malig-
nant cells [7,28]. HS, as reported previously, is the
minor type of GAGs in pancreatic carcinoma. In a
previous study [15], it has been also reported that a
type of heparan sulfate proteoglycan (HSPG), in
non-carcinomatous parenchyma of the pancreas is
higher than that in pancreatic adenocarcinoma and
the HSPG content of adenocarcinomatous parenchy-
ma is closely correlated with its degree of di¡erentia-
tion and the clinical prognosis.
Electrophoresis of isolated GalGAGs from normal
pancreas (Fig. 2A, inset) and pancreatic carcinoma
(Fig. 2B, inset) on cellulose acetate membranes, be-
fore digestion with chondroitinase B gave two bands
belonging to DS and CS. Electrophoresis of isolated
GalGAGs after digestion with chondroitinase B gave
only the CS band, revealing the degradation of DS
band. Chromatography of isolated GalGAGs from
normal pancreas on Sepharose CL-6B column re-
sulted in a major peak with a partition coe⁄cient
(Kav) 0.5 (corresponding to Mr 33-kDa) and a broad
incompletely resolved slowly eluting peak with a Kav
0.65 (corresponding to Mr 19-kDa) (Fig. 2A). Diges-
tion of GalGAGs with chondroitinase B, a lyase
which cleaves L(1^4)-galactosaminyl-iduroronic acid
bonds, and subsequent chromatography on the same
column showed that the peak of Kav 0.5 ‘disap-
peared’ and the degradation’s products (about 70%
of total uronic acid) were eluted to the Vt of the
column. The GalGAG chains in ‘disappeared’ peak
were characterized as DS chains. The GalGAG
chains in the chondroitinase B resistant peak of Kav
0.65 were characterized as CS chains. The GalGAG
chains derived from the pancreatic carcinoma were
chromatographed on Sepharose CL-6B (Fig. 2B) and
eluted as two incompletely resolved but distinct
peaks with Kav values of 0.58 (Mr 24 kDa) and
0.69 (Mr 17 kDa). Chromatography of pancreatic
carcinoma-derived GalGAGs after digestion with
chondroitinase B on the same column revealed that
the peak of Kav 0.58 had disappeared and the prod-
ucts of degradation (18% of uronic acid) were eluted
to the Vt of the column. The disappeared peak con-
tained DS chains and the chondroitinase B-resistant
material which eluted with Kav 0.69 represented the
CS chains. These results indicated that the CS and
DS chains presented in pancreatic carcinoma are of
lower molecular size as compared with those derived
Fig. 1. (A) Fractionation of GAGs (3 mg of uronic acid) from
normal pancreas (a) and pancreatic carcinoma (b) by anion-ex-
change chromatography on DEAE-Sephacel column (15U1.6
cm i.d.). The column was eluted stepwise with 3 vols. of 0.1 M
NaCl and 10 vols. of a NaCl linear gradient ranging from 0.1
to 1.2 M NaCl. Fractions of 3.1 ml were collected and analyzed
for uronic acid. (B) Electrophoresis of fractionated populations
from normal pancreas (N) and pancreatic carcinoma (C), on
cellulose acetate membranes using 0.1 M pyridine^0.1 M formic
acid, pH 3.1. Std, standards of HA, HS, DS and CS.
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from normal pancreas. In contrast, the HS chains
from both tissues, normal and cancerous, showed
identical chromatographic pro¢les having the same
Mr 18-kDa (¢gure not shown).
The products of digestion derived by chondroiti-
nase B (belonging to DS chains), which eluted to the
Vt of the column, and the chondroitinase B-resistant
materials (belonging to CS chains) were pooled, con-
centrated and digested with chondroitinase ABC.
The obtained unsaturated disaccharides were ana-
lyzed by HPLC. The results on disaccharide compo-
sition in DS and CS chains are presented in Fig. 2C.
In normal pancreas, the predominant disaccharide
units in both DS and CS chains are the 4-sulfated
disaccharides (95% and 58% of total disaccharides,
respectively). In pancreatic carcinoma the sulfation
pattern of DS was almost una¡ected, but the sulfa-
tion pattern of CS was signi¢cantly altered. The re-
sults demonstrate that the CS chains in pancreatic
carcinoma were composed predominantly of 6-sul-
fated disaccharides (72%), whereas the proportion
of 4-sulfated disaccharides (9%) was signi¢cantly de-
creased. Furthermore, the proportion of non-sulfated
disaccharides (19%) of CS in pancreatic carcinoma
was markedly increased in comparison with that of
normal pancreas (5%) (Fig. 2C).
The coexistence of non-sulfated with 6-sulfated di-
saccharides in this extent, suggests that in pancreatic
carcinoma, the predominant type of GAG is an
undersulfated CS, a more primitive species found in
abundance in developing organs and in the stroma of
various epithelial tumors [29]. It is noteworthy that
similar tumor-associated changes in disaccharide
composition and sulfation pattern are also observed
in numerous carcinomas [9,11,12] with morphoge-
netic features similar to pancreatic carcinoma. Alter-
ations in sulfation pattern of CS may well re£ect
modi¢ed biological roles of this molecule between
normal and neoplastic tissues, since sulfation is a
non-random and biosynthetically regulated process
[30]. The lower molecular sizes and the more hetero-
geneity of the GalGAG chains of pancreatic carcino-
ma than those from normal tissue must be due, at
least partly, to the presence of variable, but signi¢-
cantly increased proportions of non-sulfated disac-
charides in GalGAG chains. Furthermore, the quan-
titative data revealed that the CS chains, that are
Fig. 2. Gel chromatography of GalGAGs isolated from normal
pancreas (A) and pancreatic carcinoma (B) on Sepharose CL-
6B (110U0.6 cm i.d.), before (b) and after (a) digestion with
chondroitinase B. The column was eluted with 0.5 M sodium
acetate bu¡er, pH 7.0. Fractions of 0.9 ml were collected and
analyzed for uronic acid. Insets show the electrophoretic pro-
¢les of GalGAGs isolated from both tissues before and after di-
gestion with chondroitinase B. Electrophoreses were performed
on cellulose acetate membranes as mentioned above. The disac-
charide composition of CS and DS isolated from both tissues
(C) was obtained by HPLC analyses.
6
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accumulated in the extracellular matrix of the pan-
creatic carcinoma are relatively smaller, but are
much more numerous than their normal counter-
parts. The nature of proteoglycan (PG) involved in
the accumulation of CS is unknown, but according
to previous studies [11,29], the presence of versican
and decorin is a likely candidate. The speculation
that these PGs provide the core protein for CS
chains remains to be studied.
In conclusion, the present study indicated that
pancreatic carcinoma in comparison to the normal
pancreas, contained much higher amounts of HA
and CS chains which exhibited altered sulfation pat-
tern and reduced molecular size. The present data
provide further support to the concept that the
high levels of HA correlate with poor di¡erentiation
and decreased survival rates in some human carcino-
mas, and HA is one of the key molecules implicated
in the invasive growth of carcinomas. Furthermore,
our results in pancreatic carcinoma support the con-
cept that the CS accumulation may re£ect a more
general phenomenon associated with tumor growth
and progression, since CS is markedly elevated in a
variety of mesenchymal and epithelial neoplasms.
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